send link to app

lineQDT


4.8 ( 2848 ratings )
ヘルスケア/フィットネス
開発者 Dong geon Kim
無料

Dementia Diagnosis Application Using Line Bisection Test

Introducing an innovative and user-friendly dementia diagnosis application that utilizes the Line Bisection Test for swift and convenient assessment. With just 30 trial rounds following on-screen instructions (middle, right, left), this application provides an efficient way to determine whether the individual has Alzheimers Disease (ADD) or is in a normal state (NA). In addition to the diagnostic outcome, the application generates middle, right, and left deviation results that can be referred to by medical professionals.

Key Features:

Line Bisection Test: The application employs the Line Bisection Test. Users perform 30 trials by aligning with the on-screen instructions (middle, right, left).
Quick and Accurate: With a simple and straightforward user interface, the application ensures rapid yet accurate diagnosis, providing valuable insights into the users cognitive state.
Diagnostic Outcome: Upon completing the 30 trials, the application promptly determines whether the user exhibits signs of Alzheimers Disease (ADD) or falls within the normal range (NA).
Deviation Analysis: The application generates detailed results showcasing the deviation in responses for middle, right, and left orientations. These insights can be utilized by healthcare professionals for a comprehensive assessment.
Expert Reference: The deviation analysis results are designed to assist medical experts in understanding the users cognitive performance and making informed diagnostic decisions.
User-Friendly: The applications intuitive design ensures ease of use for individuals of varying technical backgrounds, enabling widespread access and adoption.

Experience the future of dementia diagnosis with our revolutionary Line Bisection Test-based application. By combining cutting-edge technology with a user-centric approach, we aim to contribute to early detection and effective management of cognitive conditions.